Suicide gene therapy in cancer and HIV-1 infection: An alternative to conventional treatments

Saeb, Sepideh; Assche, Jeanne Van; Loustau, Thomas; Rohr, Olivier; Wallet, Clémentine; Schwartz, Christian

doi:10.1016/j.bcp.2021.114893

Cited by 13 publications

(7 citation statements)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As baculoviruses can be made to express proteins in insect cells in large amounts, they have been utilized extensively for more than three decades as a method for gene expression [ 15 ]. Recombinant baculoviruses have demonstrated the ability to infiltrate diverse mammalian cells and express foreign genes utilizing mammalian promoters [ 16 , 17 ]. Baculoviruses can act as a successful gene expression vector for the baculovirus-induced immune response in mammalian cells.…”

Section: Reviewmentioning

confidence: 99%

HIV-Encoded Gene Therapy as Anti-cancer Therapeutics: A Narrative Review

Balakrishnan,

Sathish,

Saravanan

2024

Cureus

View full text Add to dashboard Cite

Recently, there has been interest in using viruses as cancer treatments. Oncolytic virology was founded by scientists who noticed that viruses might preferentially lyse cancer cells over healthy ones. Oncolytic virotherapy has similar obstacles as other treatment approaches, gaining entry into the specific tumour cell, encountering antiviral immune responses, off-target infection and many other unfavourable circumstances in the tumour microenvironment, and a lack of unique therapeutic and predictive biomarkers. However, oncolytic viruses have emerged as the main players in the biological treatment for cancer with the use of vectors such as human adenoviruses in oncolytic virotherapy. Recent large-scale research has shown that other viruses, such as the measles virus and the herpes simplex virus (HSV), may potentially be viable options for cancer treatment. The FDA has cleared T-VEC, an HSV-based oncolytic virus, for use in biological cancer treatment after its successful completion of human clinical trials. Furthermore, the measles virus vaccine strain has shown remarkable outcomes in pre-clinical and clinical testing. The use of such modified viruses in biological cancer treatment holds promise for groundbreaking discoveries in the field of cancer research because of their therapeutic effectiveness, fewer side effects, and safety. Several other newer approaches have been used in recent years. HIV-encoded proteins are also hypothesized to promote mitochondrial homeostasis causing bystander-induced apoptosis. We provide an overview of the most recent developments in the clinical use of oncolytic virus-based biological cancer treatment in this study. This evaluation also assesses the advantages and disadvantages of the viral candidates and provides insight into their potential in the future.

show abstract

Section: Reviewmentioning

confidence: 99%

HIV-Encoded Gene Therapy as Anti-cancer Therapeutics: A Narrative Review

Balakrishnan,

Sathish,

Saravanan

2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Phage vectors are employed to transfer suicide genes encoding susceptibility factors into the targeted tumor cells in this therapy. [ 127 ] The phage‐based nanosystems exhibit the potential for prodrug therapy of strong targeting specificity, high drug bioavailability, low intrinsic toxicity, [ 107a ] and degradation rate. [ 128 ] However, phage‐based prodrug therapy still has a large room for improvement.…”

Section: Phage Nanovectors For Tumor Therapy Based On Different Pathwaysmentioning

confidence: 99%

Recent Progress in Phage‐Based Nanoplatforms for Tumor Therapy

Li,

Peng,

Feng

et al. 2023

Small

View full text Add to dashboard Cite

Nanodrug delivery systems have demonstrated a great potential for tumor therapy with the development of nanotechnology. Nonetheless, traditional drug delivery systems are faced with issues such as complex synthetic procedures, low reproducibility, nonspecific distribution, impenetrability of biological barrier, systemic toxicity, etc. In recent years, phage‐based nanoplatforms have attracted increasing attention in tumor treatment for their regular structure, fantastic carrying property, high transduction efficiency and biosafety. Notably, therapeutic or targeting peptides can be expressed on the surface of the phages through phage display technology, enabling the phage vectors to possess multifunctions. As a result, the drug delivery efficiency on tumor will be vastly improved, thereby enhancing the therapeutic efficacy while reducing the side effects on normal tissues. Moreover, phages can overcome the hindrance of biofilm barrier to elicit antitumor effects, which exhibit great advantages compared with traditional synthetic drug delivery systems. Herein, this review not only summarizes the structure and biology of the phages, but also presents their potential as prominent nanoplatforms against tumor in different pathways to inspire the development of effective nanomedicine.

show abstract

“…In the past few years, gene therapy and gene delivery methods for targeting cancer cells have evolved tremendously, leading to new frontiers and opportunities for cancer treatment. One of these approaches involves genetic modification of tumor cells by designing suicide gene therapy (SGT) known as gene‐directed enzyme/prodrug therapy (GDEPT) 3,4 …”

Section: Introductionmentioning

confidence: 99%

Escherichia coli cytosine deaminase: Structural and biotechnological aspects

Vosough,

Vafadar,

Naderi

et al. 2023

Biotech and App Biochem

View full text Add to dashboard Cite

Suicide gene therapy involves introducing viral or bacterial genes into tumor cells, which enables the conversion of a nontoxic prodrug into a toxic‐lethal drug. The application of the bacterial cytosine deaminase (bCD)/5‐fluorocytosine (5‐FC) approach has been beneficial and progressive within the current field of cancer therapy because of the enhanced bystander effect. The basis of this method is the preferential deamination of 5‐FC to 5‐fluorouracil by cancer cells expressing cytosine deaminase (CD), which strongly inhibits DNA synthesis and RNA function, effectively targeting tumor cells. However, the poor binding affinity of toward 5‐FC compared to the natural substrate cytosine and/or inappropriate thermostability limits the clinical applications of this gene therapy approach. Nowadays, many genetic engineering studies have been carried out to solve and improve the activity of this enzyme. In the current review, we intend to discuss the biotechnological aspects of Escherichia coli CD, including its structure, functions, molecular cloning, and protein engineering. We will also explore its relevance in cancer clinical trials. By examining these aspects, we hope to provide a thorough understanding of E. coli CD and its potential applications in cancer therapy.

show abstract

Suicide gene therapy in cancer and HIV-1 infection: An alternative to conventional treatments

Cited by 13 publications

References 154 publications

HIV-Encoded Gene Therapy as Anti-cancer Therapeutics: A Narrative Review

HIV-Encoded Gene Therapy as Anti-cancer Therapeutics: A Narrative Review

Recent Progress in Phage‐Based Nanoplatforms for Tumor Therapy

Escherichia coli cytosine deaminase: Structural and biotechnological aspects

Contact Info

Product

Resources

About